Monte Rosa Therapeutics(GLUE)
$8.91-0.16 (-1.76%)
GLUE
Monte Rosa Therapeutics financials statements
$8.91
At close:-0.16 (-1.76%)
Want to see GLUE full AI Analyst Report?
Monte Rosa Therapeutics (GLUE) Ratios
408 Followers
Monte Rosa Therapeutics Ratios
GLUE's free cash flow for Q3 2026 was $-42.54M. For the 2026 fiscal year, GLUE's free cash flow was decreased by $-1.56M and operating cash flow was $-40.98M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 6.12 | 2.40 | 5.07 | 10.79 | 20.96 |
| Quick Ratio | 6.12 | 2.40 | 5.07 | 10.79 | 20.96 |
| Cash Ratio | 2.02 | 1.43 | 2.75 | 2.15 | 20.80 |
| Solvency Ratio | -0.14 | -0.30 | -1.04 | -1.48 | -3.82 |
| Operating Cash Flow Ratio | -0.36 | 0.27 | -0.94 | -3.62 | -3.57 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 177.58M | $ 161.64M | $ 111.71M | $ 204.91M | $ 329.85M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.09 | 0.10 | 0.15 | 0.14 | 0.00 |
| Debt-to-Equity Ratio | 0.17 | 0.19 | 0.26 | 0.17 | 0.00 |
| Debt-to-Capital Ratio | 0.14 | 0.16 | 0.20 | 0.15 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.93 | 1.97 | 1.69 | 1.26 | 1.05 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | -28.86 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -29.86 | 0.00 |
| Debt to Market Cap | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.60 | 0.58 | 0.90 | 1.07 | 0.00 |
| Net Debt to EBITDA | 2.89 | 2.93 | 0.60 | 0.07 | 4.89 |
| Profitability Margins | |||||
| Gross Profit Margin | 93.24% | 89.26% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | -32.12% | -92.74% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | -25.36% | -82.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | -43.83% | -107.26% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | -32.12% | -92.74% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | -31.23% | -96.14% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | -31.23% | -96.14% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 97.24% | 103.66% | 100.25% | 100.00% | 100.00% |
| EBT Per EBIT | 73.28% | 86.46% | 94.21% | 96.54% | 101.48% |
| Return on Assets (ROA) | -8.61% | -16.57% | -44.56% | -31.69% | -20.19% |
| Return on Equity (ROE) | -16.57% | -32.61% | -75.51% | -39.98% | -21.28% |
| Return on Capital Employed (ROCE) | -14.10% | -28.78% | -55.73% | -35.47% | -20.84% |
| Return on Invested Capital (ROIC) | -13.56% | -28.41% | -55.05% | -35.13% | -20.84% |
| Return on Tangible Assets | -8.61% | -16.57% | -44.56% | -31.69% | -20.19% |
| Earnings Yield | -3.76% | -14.17% | -46.61% | -30.19% | -7.78% |
| Efficiency Ratios | |||||
| Receivables Turnover | 26.89 | 437.12 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 2.35 | 0.47 | 0.56 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 2.46 | 1.34 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.28 | 0.17 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.45 | 0.37 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -141.49 | -772.90 | -654.21 | 0.00 | 0.00 |
| Days of Sales Outstanding | 13.58 | 0.84 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 155.07 | 773.73 | 654.21 | 0.00 | 0.00 |
| Operating Cycle | 13.58 | 0.84 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.35 | 0.57 | -0.85 | -1.96 | -1.28 |
| Free Cash Flow Per Share | -0.42 | 0.51 | -1.22 | -2.23 | -1.48 |
| Dividend Paid and CapEx Coverage Ratio | -4.85 | 10.53 | -2.30 | -7.16 | -6.10 |
| Capital Expenditure Coverage Ratio | -4.85 | 10.53 | -2.30 | -7.16 | -6.10 |
| Operating Cash Flow Coverage Ratio | -0.58 | 0.98 | -0.95 | -1.97 | 0.00 |
| Operating Cash Flow to Sales Ratio | -0.18 | 0.56 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -2.68% | 7.41% | -21.64% | -29.32% | -7.27% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -26.58 | -7.08 | -2.15 | -3.31 | -12.85 |
| Price-to-Sales (P/S) Ratio | 8.31 | 6.78 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 4.41 | 2.30 | 1.62 | 1.32 | 2.73 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -37.37 | 13.50 | -4.62 | -3.41 | -13.75 |
| Price-to-Operating Cash Flow Ratio | -45.08 | 12.21 | -6.63 | -3.89 | -16.01 |
| Price-to-Earnings Growth (PEG) Ratio | 0.67 | 0.11 | -0.15 | -0.07 | -0.14 |
| Enterprise Value Multiple | -29.87 | -5.34 | -1.52 | -3.24 | -8.54 |
| Enterprise Value | 937.03M | 331.40M | 208.33M | 351.49M | 604.19M |
| EV to EBITDA | -29.87 | -5.34 | -1.52 | -3.24 | -8.54 |
| EV to Sales | 7.58 | 4.38 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -34.08 | 8.72 | -3.32 | -3.34 | -8.74 |
| EV to Operating Cash Flow | -41.10 | 7.89 | -4.76 | -3.80 | -10.18 |
| Tangible Book Value Per Share | 3.56 | 3.02 | 3.49 | 5.75 | 7.47 |
| Shareholders’ Equity Per Share | 3.56 | 3.02 | 3.49 | 5.75 | 7.47 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.03 | -0.04 | -0.00 | 0.00 | 0.00 |
| Revenue Per Share | 1.89 | 1.02 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.59 | -0.98 | -2.63 | -2.30 | -1.59 |
| Tax Burden | 0.97 | 1.04 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.94 | 0.97 | 1.01 |
| Research & Development to Revenue | 1.14 | 1.61 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.29 | 0.47 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.15 | 0.24 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.59 | -0.58 | 0.32 | 0.85 | 0.80 |
Currency in USD

